Variability in Antinuclear Antibody Testing to Assess Patient Eligibility for Clinical Trials of Novel Treatments for Systemic Lupus Erythematosus

ConclusionThese findings indicate that, when used for screening, IFAs can vary because of performance characteristics of kits and thus can affect determination of trial eligibility. With kits producing a significant frequency of ANA negativity, ANA status can be associated with other serologic measures as well as the presence of the IFN signature, potentially affecting responsiveness to a trial agent.

Source: Arthritis and Rheumatology - August 4, 2019 Category: Rheumatology Authors: David S. Pisetsky, Dana Kathryn Thompson, Joseph Wajdula, Annette Diehl, Sudhakar Sridharan Tags: Brief Report Source Type: research